Partner with our global central laboratory to get a jump start on your COVID-19 study.
Committed to helping our research partners
As organizations and individuals around the world continue to adapt to the coronavirus pandemic, we at ACM Global Laboratories are committed to helping our research partners work to quickly investigate vaccine and therapeutic solutions.
That's why, in addition to providing access to the right blend of scientific experts, project managers, and other professionals ready to guide your program from inception to completion, we're offering special discounts for COVID-19 related studies and an accelerated review process.
Our Testing Portfolio for COVID-19 Studies
Our global central lab offers a full range of state of the art instruments and testing platforms to facilitate viral detection and perform assays designed to support clinical trials to evaluate the safety and efficacy of vaccines and therapeutic interventions to treat COVID-19. ACM’s team of knowledgeable scientists are available to conduct immunophenotypic analysis and support the routine safety and bioanalytical studies needed to successfully complete your COVID-19 clinical trial.
With a worldwide network of wholly-owned facilities and strategic laboratory partners, we support clinical trials in more than 65 countries, including the United States, the United Kingdom, India, Singapore, and China. We are a recognized leader in global clinical trials testing. As a full-service central laboratory we proudly offer these services that are managed by our teams of dedicated professionals:
Customized sample collection kits
Dedicated project management
Expert study set up
Global logistics solutions
Specimen management experts
Reliable specimen storage options
With a focus on quality and the ability to provide the skills and bandwidth needed to deliver robust central laboratory services, our experts offer effective strategies and solutions to efficiently execute your global clinical trial. Please contact us to learn more about how we can facilitate your COVID-19 clinical trial program.